Daniel Brennan
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
19
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $2.10 | +19.05% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $22.55 | +28.60% | 5 | Oct 8, 2024 | |
| QTRX Quanterix | Maintains: Hold | $17 → $15 | $13.85 | +8.30% | 1 | Aug 9, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $2.51 | -0.40% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $613 → $670 | $555.47 | +20.62% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $182.48 | +9.60% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,364.02 | -43.55% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $71.13 | +61.68% | 3 | Apr 28, 2020 |
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $2.10
Upside: +19.05%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $22.55
Upside: +28.60%
Quanterix
Aug 9, 2024
Maintains: Hold
Price Target: $17 → $15
Current: $13.85
Upside: +8.30%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $2.51
Upside: -0.40%
Thermo Fisher
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $555.47
Upside: +20.62%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $182.48
Upside: +9.60%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,364.02
Upside: -43.55%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $71.13
Upside: +61.68%